Answers are grounded in this paper and cite their sources.
Molecular testing of indeterminate thyroid nodules has helped to reduce the burden of diagnostic surgery, associated healthcare costs, and potential complications. Current-generation tests have demonstrated improvement in diagnostic performance, but challenges remain in improving test performance and refining the scope of testing in care. Decision-making for the management of indeterminate thyroid nodules should consider cytology, clinical and sonographic features, patient values and preferences and molecular testing results, whenever available.
No takes yet. Share an insight, caveat, or question.
Raghunathan et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: